Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Structure Therapeutics Inc. - American Depositary Shares
(NQ:
GPCR
)
48.58
+0.41 (+0.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Structure Therapeutics Inc. - American Depositary Shares
< Previous
1
2
3
Next >
Could Structure Therapeutics Become the Next Novo Nordisk?
June 17, 2024
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Via
The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
June 11, 2024
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Via
The Motley Fool
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
June 10, 2024
The company is focusing on obesity treatment after its glaucoma drug failed.
Via
Investor's Business Daily
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
June 09, 2024
Structure Therapeutics has a long way to go before beating Wegovy.
Via
The Motley Fool
Top Names Performance Update - Saturday, June 8
June 08, 2024
I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone...
Via
Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
June 03, 2024
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Via
Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
June 03, 2024
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Via
Investor's Business Daily
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 03, 2024
Via
Benzinga
Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate
June 03, 2024
Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 03, 2024
Via
Benzinga
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
May 31, 2024
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.
Via
InvestorPlace
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
May 21, 2024
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
Via
Benzinga
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
May 09, 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
May 09, 2024
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
Via
InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
April 24, 2024
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Via
InvestorPlace
7 Small-Cap Stocks that Wall Street Loves for Good Reason
March 30, 2024
As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves.
Via
InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
March 15, 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
The Best-Performing U.S. IPOs Of 2023
February 04, 2024
In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year.
Via
Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
December 25, 2023
It has genuine struggles ahead, but it has some actual value in hand as well.
Via
The Motley Fool
7 Small-Cap Stocks That Wall Street Loves for Good Reason
December 22, 2023
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Via
InvestorPlace
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 19, 2023
Via
Benzinga
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
December 18, 2023
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.